Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
The AEW star gets candid about loss, love, life on the road, and the role…
Sara Carter, the former investigative journalist and Fox News contributor now serving as White House…
Weed may be legal in much of America, but for non-citizens, one hit, one job,…
A new survey conducted by Pew Research examined what is considered “morally acceptable” in 25 countries.…
The agency has quietly sent a CBD compliance and enforcement policy to the White House…
When renowned US film director Paul Thomas Anderson and production designer Florencia Martin visited the…